Endo Health Solutions (ENDP
) issues a statement
in response to the FDA's decision to deny its citizen petition and approve a generic version
of Lidoderm, saying it's disappointed with the outcome. The company says approval of a generic version without requiring clinical endpoint studies is inadequate to establish the safety and efficacy of the medication.